ASCO® 2024 Insights: "LAURA Study - Osimertinib After Definitive CRT in Patients With Unresectable Stage 3 EGFRm NSCLC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "LAURA Study - Osimertinib After Definitive CRT in Patients With Unresectable Stage 3 EGFRm NSCLC"

By ecancer FEATURING Suresh Ramalingam

0 views

June 21, 2024

Comments 0

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

2024 ASCO® Annual Meeting Insights Hub: Lung Videos

17:22

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths…

Feat. A. Chiang

40:00

ecancer

ASCO® 2024: Highlights and Analysis of Key Solid Cancer Trials

Feat. B. Gyawali

04:26

ecancer

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance vs. Local C…

Feat. P. Iyengar

View All

The Use of IO Doublet in PD-L1-Negative NSCLC